Park Ha Biological Technology is trading 13.39% up at $2.71, with no clear company-specific announcement or filing explaining the October 7 move. - Recent lawsuit-related coverage predates this session. - Reuters reported investors were cautious as Treasury yields and oil rose ahead of Federal Reserve minutes, while the provided sector context showed biotech lower. Those trends do not explain the stock’s gain.